Nuestro blog

We know that a patient-centric approach to clinical trials generally leads to higher compliance and retention rates. DCTs are more convenient for participants.

In the first of our two-part series exploring minority participation in clinical trial research, we examine the numerous challenges to securing diversity in clinical trials and the consequences of primarily white patient populations.

ObvioHealth tackles misconceptions about decentralized clinical trials, they’re less safe, they’re always fully virtual, the data isn’t trustworthy, and so on.

BYOD ePRO models deliver a range of benefits to clinical trial stakeholders, including increased engagement, reduced site team burden, and more.

Digital therapeutics are playing an increasing role in mental health care. Ensuring that these DTx products meet quality thresholds is key to effective care.

One of the keys to optimizing ePRO is deploying artificial intelligence (AI) to support human participants and clinical teams.

The unique challenges associated with women’s health, and women as a cohort, make clinical research in this sector especially difficult. DCTs are helping to tackle the obstacles.

eConsent can mitigate these shortcomings by providing flexibility and engagement that empower patients with information and sponsors with data integrity.

Diversity in clinical trials is a scientific imperative, a moral and ethical necessity—and a longstanding challenge in clinical research. DCTs are evolving the industry status quo.

Combining the ease of ePRO with expert rating—patient convenience with the objectivity of experts—facilitates more accurate data collection.